Samsung Biologics signs $514m manufacturing contract with US-based pharma company

Published: 30-Apr-2025
Manufacturing Finance

The six year contract manufacturing deal will provide see Samsung Biologics produce pharmaceutical products for an undisclosed, US-based company

South Korean CDMO Samsung Biologics has signed a novel manufacturing agreement with an undisclosed US pharmaceutical company worth 737.3 billion won, equating to $514m. 

Currently, Samsung Biologics is unable to disclose the identity of the US-based partner due to contractural obligations.

Through this contract manufacturing agreement, the biologics CDMO will be responsible for the production of pharmaceutical products for the US company.

This deal constitutes around 16.2% of Samsung Biologics' consolidated revenue from 2024, and follows the company's signing of a behemoth 2.07tr won ($1.45bn) contract with an undisclosed European pharmaceutical company.

The agreement will be active until the end of 2031.

Currently, Samsung Biologics works with 85% of the top 20 pharmaceutical companies, with the company's backlog standing at $8.27bn at the end of 2024. 

 

You may also like

  • Companies:
  • Samsung Biologics
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Beyond capacity: biopharma companies need agile manufacturing partners

Read more
To succeed in the biopharmaceutical industry, organisations require a future-focused lens. What is in the clinical pipeline? What will demand look like in 5 years? When are key patents expiring and how will that impact competition?

Trending Articles

  1. Roquette debuts Health & Pharma Solutions, Nutrition & Bioindustry subsidiaries The company has created two new organisations; Roquette Health & Pharma and Roquette Nutrition & Bioindustry, following its acquisition of IFF Pharma Solutions
  2. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Energy efficiency in pure steam generation: how small adjustments can lead to big savings Pharmaceutical manufacturers face a twofold challenge: they not only have to produce vital medicines faster and more efficiently, but they must also reduce energy and media consumption as well as costs
  4. AnalytiChem debuts branded Redipor culture media The branded culture media line combines the expertise of BioTrading, Redipor by Cherwell and NEL to provide customers with tailored batch sizes, formulations and packaging solutions
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

Boosting Sustainability and Efficiency in Pharma Manufacturing

14 May 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Beyond capacity: biopharma companies need agile manufacturing partners

To succeed in the biopharmaceutical industry, organisations require a future-focused lens. What is in the clinical pipeline? What will demand look like in 5 years? When are key patents expiring and how will that impact competition?
Manufacturing

Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company

The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031
Manufacturing

Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant

The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Manufacturing

Navigating biologics chemistry, manufacturing and controls with an innovative CDMO

Drug development is a journey. From the initial discovery of a druggable target through to commercialisation, biopharma companies face an uphill battle when designing, optimising and advancing safe and efficacious drugs
Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Samsung enters agreement on manufacture of antibody cancer drug

Building on their existing manufacturing agreement, Bristol Myers Squibb and Samsung Biologics have announced an agreement for large-scale manufacture of a Bristol Myers Squibb commercial antibody cancer drug substance
Manufacturing

Unearthing the potential of CDMO services to accelerate complex biologics development

The biologics landscape continues to transform in response to technological advancements and a growing understanding of molecular biology and biochemistry. As a result, an influx of both novel and complex therapeutics is entering the development pipeline, including bispecific antibodies (BsAbs), fusion proteins and antibody-drug conjugates (ADCs). However, these new moieties bring unique and potentially unfamiliar development and manufacturing difficulties
Subscribe now